NYSE · BHCHealthcarePharmaceuticals

Bausch Health Companies financials

$5.80+0.52%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

Fiscal yearFY25
Dec 31
FY24
Dec 31
FY23
Dec 31
FY22
Dec 31
FY21
Dec 31
FY20
Dec 31
FY19
Dec 31
FY18
Dec 31
Revenue$10.27B$9.63B$8.76B$8.12B$8.43B$8.03B$8.60B$8.38B
Gross profit$7.25B$6.84B$6.20B$5.76B$6.04B$5.78B$6.25B$6.03B
Gross margin70.7%71.1%70.8%70.9%71.6%72.0%72.7%71.9%
Operating income$1.96B$1.79B$991.0M$454.0M$450.0M$676.0M-$203.0M-$2.39B
Net income$157.0M-$46.0M-$592.0M-$225.0M-$948.0M-$560.0M-$1.79B-$4.15B
Net margin1.5%−0.5%−6.8%−2.8%−11.2%−7.0%−20.8%−49.5%
Diluted EPS$0.42$-0.13$-1.62$-0.62$-2.64$-1.58$-5.08$-11.81
EBITDA$3.46B$3.20B$2.89B$2.75B$2.75B$2.64B$1.98B$3.34B
Operating cash flow$1.40B$1.60B$1.03B-$728.0M$1.43B$1.11B$1.50B$1.50B
Free cash flow$1.00B$1.26B$817.0M-$946.0M$1.16B$809.0M$1.23B$1.34B
Diluted shares375.0M368.0M364.9M362.0M358.9M355.0M352.1M351.3M

Balance sheet

Period endDec 31Dec 31Dec 31Dec 31Dec 31Dec 31
Cash & equivalents$1.31B$1.18B$947.0M$564.0M$582.0M$605.0M
Short-term investments$0.00$0.00$0.00$0.00——
Total debt$20.84B$21.62B$22.39B$20.77B$22.65B$23.93B
Total assets$26.37B$26.52B$27.35B$25.69B$29.20B$31.20B
Total liabilities$25.99B$26.84B$27.43B$25.43B$29.24B$30.59B
Shareholders' equity$377.0M-$322.0M-$82.0M$260.0M-$34.0M$605.0M

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology